News
Two new AECC grants for IDIBELL researchers
Ernest Nadal and Samuel Gonçalves are awarded research grants to advance in cancer research
New discoveries towards the improvement of the immunotherapy treatment of lung cancer
In recent years, immunotherapy has been consolidated as one of the new and principal hopes in the fight against cancer. This therapeutic approach is based on the fact that our immune system is constantly watching the presence of strange presences within the body and fighting them. When a tumor originates, its mutations make cancer cells […]
New drug against of the main types of lung cancer
The clinical application of an inhibitor of the SHP2 protein (also called PTPN11) could be effective, in the near future, in patients affected by one of the main types of lung cancer, the so-called Non-small cell lung cancer (NSCLC). This is the conclusion reached by an international research team including doctors Alberto Villanueva and Ernest […]
New epigenetic drug against Mantle Cell Lymphoma
A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of Barcelona, presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL), a type of cancer characterized by […]
First photoactive drug to fight Parkinson’s disease
Experts from the Institute of Neurosciences of the University of Barcelona (UB), the Bellvitge Biomedical Research Institute (IDIBELL) and Universitat Autònoma de Barcelona (UAB) design the first photoactive drug to fight Parkinson’s disease.
New non-invasive biomarker for diagnosis and prognosis in male sterility
Researchers from the Human Molecular Genetics group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Sara Larriba, have identified a new non-invasive biomarker of the presence of sperm in the testis of azoospermic men, who represent 10% of the cases of male sterility. The work, published in the prestigious international journal Human Reproduction, […]
Green light to REMAB, a new IDIBELL Spin-Off
REMAB Therapeutics, the new IDIBELL Spin-off, was officially launched by the end of April 2018. The company has doctors Rafael Mañez (IP) and Daniel Bello, from the research group on innate immunity and pathology of the critical patient, as founding partners, together with IDIBELL. REMAB’s main objective is the development of a new molecule for […]
IDIBELL hosts the ”Marie Sklodowska-Curie Individual Actions, 2018 call” Information Day
On May 10th, the “Marie Skłodowska-Curie Individual actions, 2018 call” infoday was held in the facilities of Duran i Reynals Hospital. The session, which was co-organized by the Bellvitge Biomedical Research of Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Agency for the Management of University and Research Grants (AGAUR), filled the auditorium […]
A new drug shows preclinical efficacy in Rett syndrome
A new article published in the Cell Reports describes how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome in preclinical models. The study, led by Dr. Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and […]